Priovant
Scott Mitchell is Senior Director, Analytical Development at Priovant Therapeutics. Before joining Priovant, Scott led Analytical and CMC activities at Angion. Prior to that role, he spent 17 years at Gilead Sciences, where he supported drug substance and drug product development from pre-IND through commercialization. Scott holds a BA from Gustavus Adolphus College and a Ph.D. in Pharmacy/Medicinal Chemistry from the University of Utah, and pursued post-doctoral research at the Scripps Institution of Oceanography studying marine natural products.
This person is not in any offices
Priovant
2 followers
Priovant Therapeutics is a clinical-stage biotechnology company focused on delivering novel therapies for autoimmune diseases with the heaviest patient burdens.